Horizon Pharma (HZNP): Raising PT On RPTP Deal - Mizuho

Mizuho Securities analyst, Irina Koffler, reiterated her Buy rating on Horizon Pharma (NASDAQ: HZNP) and raised her price target to $33.00 on the RPTP deal. The analyst views the deal as a sensible, accretive, "building block" deal that should continue to diversify the business away from primary care. The analyst also expects HZNP to benefit from yet another round of 9.9% price increases in Aug, in anticipation of additional contracts.

The $33PT is up from $30 and remains based on a DCF with a 13% WACC and 3% terminal growth rate.

For an analyst ratings summary and ratings history on Horizon Pharma click here. For more ratings news on Horizon Pharma click here.

Shares of Horizon Pharma closed at $18.89 yesterday.

You May Also Be Interested In

• Boston Beer Company (SAM) PT Lowered to $325 at Jefferies
• Fiserv (FI) PT Raised to $200 at Evercore ISI
• JetBlue Airways (JBLU) PT Lowered to $6 at TD Cowen